Intracellular delivery system for antibody-Peptide drug conjugates
Geoffrey Y Berguig1, Anthony J Convertine2, Shani Frayo3
1Department of Bioengineering, University of Washington, Seattle, Washington, USA; Current address: BioMarin Pharmaceutical, Novato, California, USA.
Researchers developed a novel polymeric micelle delivery system for enhanced cytosolic delivery of protein drugs, expanding antibody-drug conjugate therapy potential for cancer treatment. This system successfully suppressed tumor growth and prolonged survival in a lymphoma mouse model.
Area of Science:
- Biotechnology and Nanomedicine
- Cancer Therapy and Drug Delivery
Background:
- Current antibody-drug conjugates (ADCs) face limitations due to intracellular delivery barriers, restricting their therapeutic potential.
- Intracellular protein drugs offer enhanced selectivity for targeting dysregulated pathways in various cancers, but effective delivery remains a challenge.
Purpose of the Study:
- To develop a multifunctional polymeric delivery system for enhanced cytosolic delivery of protein drugs.
- To improve the safety, pharmacokinetics, and tumor biodistribution of antibody-drug conjugates.
- To explore new therapeutic strategies targeting intracellular pathways in hematologic cancers and other malignancies.
Main Methods:
- Development of a pH-responsive polymeric micelle carrier.
- Incorporation of endosomal-releasing activity, antibody targeting (anti-CD22 monoclonal antibody), and a biocompatible ethylene glycol component.
- In vivo evaluation in a xenograft mouse model of human B-cell lymphoma using a proapoptotic Bcl-2 interacting mediator (BIM) peptide drug.
Main Results:
- The delivery system effectively delivered the BIM peptide drug into cancer cells.
- Suppressed tumor growth throughout the treatment duration and significantly prolonged survival in the lymphoma mouse model.
- Demonstrated correlation between antitumor activity and induction of cleaved caspase-3 (Bcl-2 pathway biomarker) and decrease in Ki-67 proliferation biomarker.
Conclusions:
- The developed polymeric micelle system enhances cytosolic delivery of protein drugs, overcoming intracellular barriers for cancer therapy.
- This approach expands the therapeutic potential of ADCs to intracellular targets, including those currently considered undruggable.
- Enables tailored drug strategies for stratified patient populations and personalized medicine in oncology.
More Related Videos
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Receptor-mediated Endocytosis
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
